Sensitivity of supplementation of thyroid hormone on treatment of idiopathic short-stature children during therapy with recombinant human growth hormone.

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this randomized controlled trial publication.

This study aimed to evaluate the effects of thyroid hormone supplementation on growth rate of children with idiopathic short stature (ISS) and low-normal serum free thyroxine FT4 who were receiving growth hormone therapy.

Why It Was Studied

The researchers also selected 39 ISS children with FT4 in the upper two-thirds of the normal range as the higher FT4 group.

Who Took Part

The abstract describes 64 children taking part.

PubMed indexes the participants as children, both men and women.

How the Study Was Run

The design is described as randomized and placebo-controlled.

Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

A placebo (an inactive look-alike) gave the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group a baseline to be compared against.

What Was Measured

PubMed files the paper under topics including Growth Disorders, Human Growth Hormone, Insulin-Like Growth Factor I, Recombinant Proteins, Thyrotropin and Thyroxine.

Author keywords: free T4, idiopathic short-stature children, recombinant human growth hormone, the first year and therapeutic.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 64 children.

The publication is from 2018 (Frontiers of medicine), a journal based in China.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.